Plant-derived natural compounds targeting drug resistance in ovarian cancer: Molecular mechanisms and therapeutic perspectives

The integration of natural products with standard therapies may offer a viable strategy to overcome chemoresistance in ovarian cancer, highlighting the need for further translational and clinical investigations.

Authors

Institutions

Publication Details

Journal
Phytomedicine
Published
2026-03-12
DOI
https://doi.org/10.1016/j.phymed.2026.158065
Primary Topic
Natural Compounds in Disease Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plant-derived natural compounds targeting drug resistance in ovarian cancer: Molecular mechanisms and therapeutic perspectives

Qiang Ao, Yin Bao, Hong Zhu, Meng Wang et al.
Phytomedicine
Natural Compounds in Disease Treatment
article

Plant-derived natural compounds targeting drug resistance in ovarian cancer: Molecular mechanisms and therapeutic perspectives

Qiang Ao, Yin Bao, Hong Zhu, Meng Wang, Li Tang, Jun Gao, Yang Chen, Jun Zhu
article en

Abstract

The integration of natural products with standard therapies may offer a viable strategy to overcome chemoresistance in ovarian cancer, highlighting the need for further translational and clinical investigations.

PhytomedicineVol. 155
Dalian Institute of Chemical Physics (CN), Jiangxi Provincial Cancer Hospital (CN), First People's Hospital of Chongqing (CN)
Good health and well-being
Openalex Percentile: Top 23%
Natural Compounds in Disease Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.